ERASCA INC's ticker is and the CUSIP is 29479A108. A total of 110 filers reported holding ERASCA INC in Q3 2023. The put-call ratio across all filers is 1.50 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $465,385 | -28.6% | 236,236 | 0.0% | 0.06% | -26.8% |
| Q2 2023 | $652,011 | -8.3% | 236,236 | 0.0% | 0.08% | -37.9% |
| Q1 2023 | $711,070 | -64.4% | 236,236 | -49.0% | 0.13% | -65.1% |
| Q4 2022 | $1,995,409 | -45.9% | 462,972 | -2.0% | 0.38% | -49.4% |
| Q3 2022 | $3,685,000 | -27.4% | 472,472 | -48.1% | 0.75% | -26.5% |
| Q2 2022 | $5,075,000 | – | 911,168 | – | 1.02% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| ARCH Venture Management, LLC | 11,055,554 | $21,779,441 | 14.15% |
| EDBI Pte Ltd | 888,888 | $1,751,109 | 1.90% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 1,926,000 | $3,794,220 | 1.28% |
| Cormorant Asset Management, LP | 10,813,246 | $21,302,095 | 1.24% |
| AH Equity Partners LSV II, L.L.C. | 312,500 | $615,625 | 0.64% |
| Artal Group S.A. | 4,721,194 | $9,301 | 0.40% |
| PFM Health Sciences, LP | 3,930,633 | $7,743,347 | 0.36% |
| ARMISTICE CAPITAL, LLC | 8,356,000 | $16,461,320 | 0.25% |
| SANDERS MORRIS HARRIS LLC | 425,297 | $816,569 | 0.17% |
| Prosight Management, LP | 264,710 | $521,479 | 0.16% |